Literature DB >> 6126378

Actions of serotonin antagonists on dog coronary artery.

R M Brazenor, J A Angus.   

Abstract

Serotonin released from platelets may initiate coronary vasospasm in patients with variant angina. If this hypothesis is correct, serotonin antagonists without constrictor activity may be useful in this form of angina. We have investigated drugs classified as serotonin antagonists on dog circumflex coronary artery ring segments in vitro. Ergotamine, dihydroergotamine, bromocriptine, lisuride, ergometrine, ketanserin, trazodone, cyproheptadine and pizotifen caused non-competitive antagonism of serotonin concentration-response curves. In addition, ketanserin, trazodone, bromocriptine and pizotifen inhibited noradrenaline responses in concentrations similar to those required for serotonin antagonism. All drugs with the exception of ketanserin, cyproheptadine and pizotifen showed some degree of intrinsic constrictor activity. Methysergide antagonized responses to serotonin competitively but also constricted the coronary artery. The lack of a silent competitive serotonin antagonist precludes a definite characterization of coronary serotonin receptors at this time. However, the profile of activity observed for the antagonist drugs in the coronary artery differs from that seen in other vascular tissues. Of the drugs tested, ketanserin may be the most useful in variant angina since it is a potent 5HT antagonist, lacks agonist activity and has alpha-adrenoceptor blocking activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6126378     DOI: 10.1016/0014-2999(82)90346-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

1.  Influence of mouse genotype on passive systemic anaphylaxis by immune complexes.

Authors:  A Portolés; J M Rojo; R Díaz
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

2.  Aggregating human platelets cause direct contraction and endothelium-dependent relaxation of isolated canine coronary arteries. Role of serotonin, thromboxane A2, and adenine nucleotides.

Authors:  D S Houston; J T Shepherd; P M Vanhoutte
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

3.  Modification of the ischaemic-induced contraction in the sheep circumflex coronary artery by various pharmacological antagonists.

Authors:  Y W Kwan; R M Wadsworth; K A Kane
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

4.  5-HT1-like receptors requiring functional cyclo-oxygenase and 5-HT2 receptors independent of cyclo-oxygenase mediate contraction of the human umbilical artery.

Authors:  S J MacLennan; M J Whittle; J C McGrath
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

5.  Trazodone overdose-induced Prinzmetal's angina pectoris.

Authors:  Bhesh Raj Karki; Paritosh Prasai; Asim Ruhela; Yub Raj Sedhai
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-09-25

6.  Mechanisms of the ergonovine-induced vasoconstriction in the rabbit main coronary artery.

Authors:  A Suyama; H Kuriyama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-07       Impact factor: 3.000

Review 7.  Serotonin and the vascular system. Role in health and disease, and implications for therapy.

Authors:  D S Houston; P M Vanhoutte
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

8.  Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors.

Authors:  A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-06       Impact factor: 3.000

9.  Catecholamine release and potentiation of thromboxane A2 production by nicotine in the greyhound.

Authors:  G J Dusting; D M Li
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

10.  Ketanserin causes surmountable antagonism of 5-hydroxytryptamine-induced contractions of large coronary arteries of dog.

Authors:  M Frenken; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-01       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.